<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37529783</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2452-2473</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Turkish journal of emergency medicine</Title><ISOAbbreviation>Turk J Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study.</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>155</EndPage><MedlinePgn>149-155</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/tjem.tjem_363_22</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Ongoing symptomatic coronavirus disease 2019 (OSC) is defined as persistent symptoms beyond 4 weeks of acute illness. OSC leads to prolonged hospitalization and oxygen dependence. We aimed to find the outcome of Janus kinase inhibitors (JAKi) as a steroid-sparing agent to treat OSC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this single-center case-controlled study comparing JAKi and corticosteroids in OSC cases, data of 41 cases out of 86 were included - 21 in the JAKi group and 20 in the corticosteroid group from 4 weeks of acute illness to the next 4 weeks. Clinical parameters and inflammatory markers were recorded. The primary outcome was to compare the proportion of patients who were able to maintain oxygen saturation &#x2265;95% with any oxygen supplementation in the two groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The baseline clinical and demographic characteristics were similar in the two groups. The age was 53.65 &#xb1; 9.8 years and 51.48 &#xb1; 14.0 years in the corticosteroid group and JAKi group, respectively. At the baseline, 85% of patients in the corticosteroid group and 85.8% in the JAKi group were on oxygen support. The most common symptom in both groups was breathlessness followed by cough. Twenty percent of patients in the JAKi group received baricitinib and the remaining were given tofacitinib. At the time of follow-up, the majority of cases had a significant reduction in C-reactive protein (CRP) and D-dimer; however, the change in CRP and D-dimer was similar in both groups. The number of patients off oxygen support at 4 weeks was higher in the JAKi group (85% in the corticosteroid group vs. 95.2% in the JAKi group, <i>P</i> = 0.269), and the median time to liberation from oxygen support was significantly lower in JAKi group (19 days in corticosteroid group vs. 9 days in JAKi group, <i>P</i> &lt; 0.001). The frequency of any adverse event was also higher in the corticosteroid group (70% vs. 23.8%, <i>P</i> = 0.003).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">JAKi can be used as immunomodulatory drugs in hypoxic OSC cases having evidence of ongoing inflammation.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Turkish Journal of Emergency Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Pawan Kumar</ForeName><Initials>PK</Initials><Identifier Source="ORCID">0000-0002-3212-9875</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Pt BDS Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Vinod Kumar</ForeName><Initials>VK</Initials><Identifier Source="ORCID">0000-0002-2479-2837</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Pt BDS Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalwani</LastName><ForeName>Lokesh Kumar</ForeName><Initials>LK</Initials><Identifier Source="ORCID">0000-0002-7652-309X</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Pt BDS Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaudhry</LastName><ForeName>Dhruva</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5138-2908</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Pt BDS Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Govindagoudar</LastName><ForeName>Manjunath B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0003-2704-0873</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Pt BDS Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sriram</LastName><ForeName>Chaudhari Pramod</ForeName><Initials>CP</Initials><Identifier Source="ORCID">0000-0002-7683-2634</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Pt BDS Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahuja</LastName><ForeName>Aman</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0307-3427</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Pt BDS Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Turk J Emerg Med</MedlineTA><NlmUniqueID>101681782</NlmUniqueID><ISSNLinking>2452-2473</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Baricitinib</Keyword><Keyword MajorTopicYN="N">Janus kinase inhibitors</Keyword><Keyword MajorTopicYN="N">long coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">postcoronavirus disease</Keyword><Keyword MajorTopicYN="N">tofacitinib</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37529783</ArticleId><ArticleId IdType="pmc">PMC10389097</ArticleId><ArticleId IdType="doi">10.4103/tjem.tjem_363_22</ArticleId><ArticleId IdType="pii">TJEM-23-149</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkota HR, Nune A. Long COVID from rheumatology perspective &#x2013; A narrative review. Clin Rheumatol. 2022;41:337&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629735</ArticleId><ArticleId IdType="pubmed">34845562</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence: Clinical Guidelines. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. National Institute for Health and Care Excellence (UK) Copyright&#xa9; NICE 2020. 2020</Citation></Reference><Reference><Citation>Esenda&#x11f;li D, Yilmaz A, Ak&#xe7;ay &#x15e;, &#xd6;zl&#xfc; T. Post-COVID syndrome: Pulmonary complications. Turk J Med Sci. 2021;51:3359&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8771021</ArticleId><ArticleId IdType="pubmed">34284532</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18:799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya A, Sarma P, Kaur H, Kumar S, Bhattacharyya J, Prajapat M, et al. COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis. Indian J Pharmacol. 2021;53:499&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8764981</ArticleId><ArticleId IdType="pubmed">34975140</ArticleId></ArticleIdList></Reference><Reference><Citation>Seif F, Aazami H, Khoshmirsafa M, Kamali M, Mohsenzadegan M, Pornour M, et al. JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol. 2020;181:467&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270061</ArticleId><ArticleId IdType="pubmed">32392562</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh PK, Lalwani LK, Govindagoudar MB, Aggarwal R, Chaudhry D, Kumar P, et al. Tofacitinib associated with reduced intubation rates in the management of severe COVID-19 pneumonia: A preliminary experience. Indian J Crit Care Med. 2021;25:1108&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8645820</ArticleId><ArticleId IdType="pubmed">34916741</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384:795&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;385:406&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220898</ArticleId><ArticleId IdType="pubmed">34133856</ArticleId></ArticleIdList></Reference><Reference><Citation>Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42:2270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928982</ArticleId><ArticleId IdType="pubmed">33448289</ArticleId></ArticleIdList></Reference><Reference><Citation> [Last accessed on 2022 Nov 18];Clinical Management Protocol for COVID-19 Government of India. 2022  Available from:https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf .</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Weerahandi H, Hochman KA, Simon E, Blaum C, Chodosh J, Duan E, et al. Post-discharge health status and symptoms in patients with severe COVID-19. J Gen Intern Med. 2021;36:738&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808113</ArticleId><ArticleId IdType="pubmed">33443703</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi M, Leelaviwat N, Eshak N, Mekraksakit P, Nugent K, Payne JD. COVID-19 discharge and follow-up recommendations. Proc (Bayl Univ Med Cent) 2020;34:73&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785155</ArticleId><ArticleId IdType="pubmed">33456149</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee J, Canamar CP, Voyageur C, Tangpraphaphorn S, Lemus A, Coffey C, Jr, et al. Mortality and readmission rates among patients with COVID-19 after discharge from acute care setting with supplemental Oxygen. JAMA Netw Open. 2021;4:e213990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017465</ArticleId><ArticleId IdType="pubmed">33792728</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutou AK, Asimakos A, Kortianou E, Vogiatzis I, Tzouvelekis A. Long COVID-19 pulmonary sequelae and management considerations. J Pers Med. 2021;11:838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8469288</ArticleId><ArticleId IdType="pubmed">34575615</ArticleId></ArticleIdList></Reference><Reference><Citation>Umemura Y, Mitsuyama Y, Minami K, Nishida T, Watanabe A, Okada N, et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study. Int J Infect Dis. 2021;108:454&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146615</ArticleId><ArticleId IdType="pubmed">34048887</ArticleId></ArticleIdList></Reference><Reference><Citation>Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">35081280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriya B, Cohen MD, Keystone E. Baricitinib in rheumatoid arthritis: Evidence-to-date and clinical potential. Ther Adv Musculoskelet Dis. 2017;9:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315227</ArticleId><ArticleId IdType="pubmed">28255337</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Caricchio R, Casanova JL, Combes AJ, Diamond B, Fox SE, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131:e154886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, et al. COVID-19 and autoimmunity. Autoimmun Rev. 2020;19:102597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289100</ArticleId><ArticleId IdType="pubmed">32535093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>